<DOC>
	<DOCNO>NCT00554723</DOCNO>
	<brief_summary>CHIMES double blind , placebo control , randomize , multicenter study test hypothesis NeuroAid superior placebo reduce neurological deficit improve functional outcome patient cerebral infarction intermediate range severity .</brief_summary>
	<brief_title>CHInese Medicine NeuroAid Efficacy Stroke Recovery</brief_title>
	<detailed_description>Stroke major cause death disability . Previous clinical study perform China show NeuroAiD increase stroke patients'recovery term neurological disability functional outcome { Chen et al,2009 } thus may beneficial part post-stroke rehabilitation programme . In CHIMES study , seek test hypothesis NeuroAiD superior placebo reduce neurological deficit improve functional outcome patient recruit within 72 h ischemic stroke intermediate range severity { 6 &lt; _NIHSS &lt; _14 } .More detail study protocol recently publish { Venketasubramanian et al,2009 } .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Subject age 18 year old ( Singapore 21 year legal age consent ) Subject antiplatelet therapy Subject present prestroke Modified Rankin Scale inferior equal 1 Female subject eligible participate trial nonchildbearing potential ( i.e . physiologically incapable become pregnant , include female post menopausal ) Subject his/her legally acceptable representative willing provide write informed consent Subject present cerebral infarction compatible imaging Computed Tomography ( CT ) scan Magnetic Resonance Imaging ( MRI ) Time window le 72 hour symptom onset Subject cerebral infarction intermediate severity range : 6 ≤ NIHSS ≤ 14 Subjects deem unstable investigator thrombolysis treatment Subject evidence intracerebral hemorrhage brain CT scan MRI Subject rapidly improve neurological deficit Subject definite indication fulldose longterm anticoagulation therapy Subject significant nonischemic brain lesion could affect function disability Subject coexist systemic disease : terminal cancer , renal failure ( creatinine &gt; 200 μmol/L , know ) , cirrhosis , severe dementia psychosis Subject participate another clinical trial within last three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Cerebral infarct</keyword>
	<keyword>Recovery</keyword>
	<keyword>Double blind</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo</keyword>
	<keyword>Traditional Chinese Medicine</keyword>
	<keyword>Neuroaid</keyword>
</DOC>